logo
Plus   Neg
Share
Email

Vertex Pharma: NHS England To Expand Reimbursement Agreement To Include KAFTRIO

Vertex Pharmaceuticals Incorporated (VRTX) has expanded its reimbursement agreement with NHS England for the company's cystic fibrosis medicines to include KAFTRIO, in a combination regimen with KALYDECO 150 mg. The expanded agreement includes reimbursed access to Vertex's currently licensed medicines - KALYDECO, ORKAMBI and SYMKEVI, as well as the triple combination therapy if approved.

The European Medicines Agency's Committee, CHMP, recently adopted a positive opinion for KAFTRIO in a combination regimen with KALYDECO 150 mg to treat people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation or two F508del mutations in the cystic fibrosis transmembrane conductance regulator gene.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Macy's is offering a sneak peek of its Black Friday deals for this year, so that shoppers can get a head start on finding some of the best deals. The department store has unveiled its Black Friday deals that will be available next month across categories, including fashion, fine jewelry, tech, beauty, toys and home specials. Some of the deals will be available for as low as $5. Italy's antitrust watchdog has opened an investigation against Google for an alleged abuse of dominant position in the Italian market for display advertising. This refers to the space publishers and website owners make available for the display of advertising content. Shares of Deutsche Bank AG were gaining around 3 percent in German trading after the banking major reported Wednesday a profit in its third quarter, compared to prior year's loss mainly driven by strong Investment Bank revenues. Looking ahead, the bank said it remains on track to meet all financial and strategic targets related to its transformation plan.
Follow RTT